RT Journal Article SR Electronic T1 Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? JF Breathe JO Breathe FD European Respiratory Society SP 210056 DO 10.1183/20734735.0056-2021 VO 17 IS 3 A1 Adilia Warris YR 2021 UL http://breathe.ersjournals.com/content/17/3/210056.abstract AB Macrolides should not be used as first-line therapy for community-acquired pneumonia in children as no clinical benefit is shown and widespread use is associated with an emerging increase in macrolide resistance amongst S. pneumoniae and M. pneumoniae https://bit.ly/3yQuedF